Novel chimeric antigen receptor modified T cells against IGF receptor for osteosarcoma

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09648
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Nagoya University
• Principal Investigator: NIshio Nobuhiro 名古屋大学, 医学部附属病院, 特任助教 (00586430)
• Co-Investigator(Kenkyū-buntansha): 中沢 洋三 信州大学, 医学部, 助教 (60397312)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: キメラ抗原受容体 / 骨肉腫

Outline of Final Research Achievements

Genetically modified T cell therapy using chimeric antigen receptor (CAR) (CAR - T therapy) has been shown to be promising as a new cancer treatment method, and application to various cancers is expected. In this study, we developed a piggyBac transposon vector for novel chimeric antigen receptor genetically modified T cells for the antigen expressed on osteosarcoma cells and our culture method enabling high transduction efficiency using the piggyBac transposon gene transfer method. The novel CAR-T cells in this study exerted potent killing activity against osteosarcoma cells. Based on this study, we could obtain baseline data of novel immunotherapy for osteosarcoma.

Free Research Field

小児血液がん